(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 May 2009 (14.05.2009)

PCT

(10) International Publication Number
WO 2009/060198 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/22* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/GB2008/003745

(22) International Filing Date:
7 November 2008 (07.11.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/987,015	9 November 2007 (09.11.2007)	US
61/106,047	16 October 2008 (16.10.2008)	US
61/108,023	24 October 2008 (24.10.2008)	US

(71) Applicants: **PEREGRINE PHARMACEUTICALS, INC.** [US/US]; 14272 Franklin Avenue, Suite 100, Tustin, CA 92780 (US). **AFFITECH AS** [NO/NO]; Oslo Research Park, Gaustadallèen 21, N-0349 Oslo (NO).

(71) Applicant *(for BB only)*: **OWEN, Deborah Jane** [GB/GB]; Frank B. Dehn & Co., St. Bride's House, 10 Salisbury Square, London EC4Y 8JD (GB).

(72) Inventors: **KAVLIE, Anita**; Stromsborgveien 39H, N-0287 Oslo (NO). **SCHLUNEGGER, Kyle**; 27912 Perales, Mission Viejo, CA 92692 (US).

(74) Agent: **FRANK B. DEHN & CO.**; St Bride' s House, 10 Salisbury Square, London EC4Y 8JD (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(54) **Title:** ANTI-VEGF ANTIBODY COMPOSITIONS AND METHODS

(57) **Abstract:** Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.

WO 2009/060198 A1